Results 281 to 290 of about 103,481 (331)

Relative efficacy of GLP‐1 and GLP‐1/GIP receptor agonists in the prevention of alcohol‐use disorders using a target trial emulation approach

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims There is growing evidence that the GLP‐1 system is implicated in alcohol and other substance use disorders, and that GLP‐1‐based therapies may have therapeutic relevance in alcohol use disorder (AUD). We aimed to determine the impact of GLP‐1 based therapies on incident AUDs in a real‐world setting in patients with T2D.
Alex E. Henney, David R. Riley, Megan Heague, Carl A. Roberts, Theresa J. Hydes, Matthew Anson, David M. Hughes, Uazman Alam, Daniel J. Cuthbertson   +8 more
wiley   +1 more source

Psychiatric effects of GLP‐1 receptor agonists: A systematic review of emerging evidence

Diabetes, Obesity and Metabolism, EarlyView.
Abstract This systematic review examines the current literature on glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs)‐associated psychiatric manifestations, including depression, suicidality, eating disorders, substance use disorders (SUD) and schizophrenia spectrum disorders.
Brianna Sa, Anthony Maristany, Ashwin Subramaniam, Ryan Guillen, Brooke Buonocore, Audrey Smith, Sean E. Oldak, Vanessa Padilla   +7 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dopamine Agonists

Seminars in Neurology, 2001
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire   +2 more sources